Nivolumab and XELOX Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Nivolumab and XELOX Therapy, 2026, version number 2a, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6444/843_Nivolumab_and_XELOX.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER-2 negative advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), or esophageal adenocarcinoma (EAC), whose tumours express PD-L1 (CPS) >= 5. 3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations Biomarkers Cancer types Therapies
HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Stomach Adenocarcinoma Capecitabine, Nivolumab, Oxaliplatin
HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Nivolumab, Oxaliplatin
HSE (1) HER2-negative, PD-L1 (CPS) >= 5 Esophageal Adenocarcinoma Capecitabine, Nivolumab, Oxaliplatin